Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
Advertisement

Starpharma ready to slip lubricated condom into market

Starpharma’s VivaGel condom is a world-first product and the only condom of its type that provides barrier protection and incorporates a proprietary anti-viral compound

Trevor Hoey

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Shares in Starpharma Holdings have trailed off since a spike of some 40 per cent saw them hit a 12-month high of 99¢ in July. This came on the back of news regarding conformity assessment certification for the VivaGel condom by the Australian Therapeutic Goods Administration.

At that stage, Starpharma mentioned its marketing partner, Ansell . planned to launch the VivaGel condom under the LifeStyles Dual Protect trademark in the coming months following listing on the Australian Register of Therapeutic Goods.

It was highlighted at the time that TGA certification would also support certain regulatory processes in other markets. The VivaGel condom is a world-first product and the only condom of its type that provides barrier protection and incorporates a proprietary anti-viral compound in the lubricant.

Taking into account royalties from the distribution of VivaGel condoms, Canaccord rated Starpharma a “buy” with a 12-month price target of $1.12. Photo: Robert Banks

While this is the backdrop to the story, the big news should come in the next week. Starpharma noted at the start of October that necessary preparations had been made, including manufacture of launch supplies, to bring the product to market in Australia this month.

Taking into account royalties from the distribution of VivaGel condoms, combined with other projects in trial phases, analysts at Canaccord rate Starpharma a “buy" with a 12-month price target of $1.12.

There has been recent promising news flow from Starpharma, with the group announcing it had completed preliminary analyses of the pharmacokinetics of docetaxel, its patented formulation of the widely used cancer drug which also incorporates the company’s proprietary dendrimers to improve delivery.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Healthcare & fitness

Fetching latest articles

Most Viewed In Companies